| pubmed-article:12814672 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12814672 | lifeskim:mentions | umls-concept:C0376358 | lld:lifeskim |
| pubmed-article:12814672 | lifeskim:mentions | umls-concept:C0001758 | lld:lifeskim |
| pubmed-article:12814672 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:12814672 | lifeskim:mentions | umls-concept:C0032743 | lld:lifeskim |
| pubmed-article:12814672 | lifeskim:mentions | umls-concept:C0392752 | lld:lifeskim |
| pubmed-article:12814672 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:12814672 | pubmed:dateCreated | 2003-6-19 | lld:pubmed |
| pubmed-article:12814672 | pubmed:abstractText | The evaluation of the efficacy of the treatment of men with prostate cancer is largely based on post treatment levels of PSA. An increase in PSA or biochemical recurrence is the first sign of recurrent disease and precedes a clinically detectable recurrence by months to years. Digital rectal examination and conventional imaging techniques are not sensitive to detect a local recurrence. A metabolic imaging technique, which is not dependent on anatomical distortions, could be of use. In this study we investigated 11C-choline positron emission tomography (PET) for the evaluation after treatment of localized prostate cancer. | lld:pubmed |
| pubmed-article:12814672 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12814672 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12814672 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12814672 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12814672 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12814672 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12814672 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:12814672 | pubmed:issn | 0302-2838 | lld:pubmed |
| pubmed-article:12814672 | pubmed:author | pubmed-author:VaalburgWW | lld:pubmed |
| pubmed-article:12814672 | pubmed:author | pubmed-author:ElsingaP HPH | lld:pubmed |
| pubmed-article:12814672 | pubmed:author | pubmed-author:PruimJJ | lld:pubmed |
| pubmed-article:12814672 | pubmed:author | pubmed-author:de JongI JIJ | lld:pubmed |
| pubmed-article:12814672 | pubmed:author | pubmed-author:MensinkH J... | lld:pubmed |
| pubmed-article:12814672 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12814672 | pubmed:volume | 44 | lld:pubmed |
| pubmed-article:12814672 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12814672 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12814672 | pubmed:pagination | 32-8; discussion 38-9 | lld:pubmed |
| pubmed-article:12814672 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:12814672 | pubmed:meshHeading | pubmed-meshheading:12814672... | lld:pubmed |
| pubmed-article:12814672 | pubmed:meshHeading | pubmed-meshheading:12814672... | lld:pubmed |
| pubmed-article:12814672 | pubmed:meshHeading | pubmed-meshheading:12814672... | lld:pubmed |
| pubmed-article:12814672 | pubmed:meshHeading | pubmed-meshheading:12814672... | lld:pubmed |
| pubmed-article:12814672 | pubmed:meshHeading | pubmed-meshheading:12814672... | lld:pubmed |
| pubmed-article:12814672 | pubmed:meshHeading | pubmed-meshheading:12814672... | lld:pubmed |
| pubmed-article:12814672 | pubmed:meshHeading | pubmed-meshheading:12814672... | lld:pubmed |
| pubmed-article:12814672 | pubmed:meshHeading | pubmed-meshheading:12814672... | lld:pubmed |
| pubmed-article:12814672 | pubmed:meshHeading | pubmed-meshheading:12814672... | lld:pubmed |
| pubmed-article:12814672 | pubmed:meshHeading | pubmed-meshheading:12814672... | lld:pubmed |
| pubmed-article:12814672 | pubmed:meshHeading | pubmed-meshheading:12814672... | lld:pubmed |
| pubmed-article:12814672 | pubmed:meshHeading | pubmed-meshheading:12814672... | lld:pubmed |
| pubmed-article:12814672 | pubmed:meshHeading | pubmed-meshheading:12814672... | lld:pubmed |
| pubmed-article:12814672 | pubmed:meshHeading | pubmed-meshheading:12814672... | lld:pubmed |
| pubmed-article:12814672 | pubmed:meshHeading | pubmed-meshheading:12814672... | lld:pubmed |
| pubmed-article:12814672 | pubmed:meshHeading | pubmed-meshheading:12814672... | lld:pubmed |
| pubmed-article:12814672 | pubmed:meshHeading | pubmed-meshheading:12814672... | lld:pubmed |
| pubmed-article:12814672 | pubmed:meshHeading | pubmed-meshheading:12814672... | lld:pubmed |
| pubmed-article:12814672 | pubmed:meshHeading | pubmed-meshheading:12814672... | lld:pubmed |
| pubmed-article:12814672 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12814672 | pubmed:articleTitle | 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. | lld:pubmed |
| pubmed-article:12814672 | pubmed:affiliation | Department of Urology, Groningen University Hospital, PO Box 30.001, 9700 RB Groningen, The Netherlands. i.j.de.jong@chir.azg.nl | lld:pubmed |
| pubmed-article:12814672 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12814672 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:12814672 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:12814672 | pubmed:publicationType | Evaluation Studies | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12814672 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12814672 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12814672 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12814672 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12814672 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12814672 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12814672 | lld:pubmed |
